Merck | MRK - Interest Expense On Debt


Merck reported $412M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Abbott USD 42M 2M Dec/2025
ALKERMES USD 12.28M 7.63M Dec/2025
Amgen USD 653M 32M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Coherus Biosciences USD 2.25M 76K Dec/2025
Drreddys Laboratories INR 944M 127M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
J&J USD 18M 290M Sep/2025
Medtronic USD 181M 0 Dec/2025
Merck USD 412M 85M Dec/2025
Novartis USD 304M 23M Dec/2025
Novartis USD 281M 8M Sep/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Pacira USD 3.89M 387K Dec/2025
Perrigo USD 10.08B 10.04B Sep/2025
Pfizer USD 711M 59M Dec/2025
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 10.67M 636K Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Sanofi EUR -25M 99.78M Dec/2025
United Therapeutics USD 3.1M 100K Dec/2025
Zoetis USD 57M 1000K Dec/2025